Encorafenib & Binimetinib Treatment

DRUG2 trials

Sponsors

Pfizer, SRH Wald-Klinikum Gera GmbH

Conditions

Melanoma BRAF V600E/K MutatedSolid Tumors

Phase 4

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

RecruitingNCT05203172

PfizerSolid Tumors

Start: 2022-07-05End: 2029-07-31Target: 46Updated: 2026-04-07

Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib

WithdrawnNCT07092410

SRH Wald-Klinikum Gera GmbHMelanoma BRAF V600E/K Mutated

Start: 2025-08-01End: 2030-08-01Updated: 2026-04-21